The agency said it is sensitive to stakeholder concerns and is working with MACs to adjust claims processing systems.
The ctDNA test will be covered for all US fee-for-service Medicare patients with advanced (Stage IIIB/IV) NSCLC who meet specific clinical criteria.
An opinion piece appearing at Stat News calls the CMS decision to limit access to next-generation sequencing-based tests for hereditary cancers a "grievous error."
Proposals from two HHS agencies look to encourage patient access to data and interoperability in research and clinical practice, including Sync for Genes.
CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.
In a letter to CMS, AMP made a case for crosswalking existing CPT codes for BRCA1/2 testing to codes that more accurately reflect the work required to analyze these genes.
The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.
New drugs, tests, and policies suggest steady and continued future growth in the space, though public awareness of personalized medicine continues to lag.
The effort is one of five being undertaken by MDIC's Clinical Diagnostic Program designed to expedite the regulatory process for clinical diagnostics.
The National Society of Genetic Counselors has garnered bipartisan support for H.R. 7083 by emphasizing healthcare savings from using counselors to drive appropriate test use.
Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.
Wired reports that researchers have shown they could reprogram a DNA-based computer.
Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.
In Science this week: whole-genome sequencing of single sperm cells, and more.